EUCTR2009-011056-21-ES进行中（未招募）不适用
Estudio fase II, multicéntrico, abierto, para comparar la eficacia y seguridad de RAD001 en primera línea seguido de sunitinib en segunda línea frente a sunitinib en primera línea seguido de RAD001 en segunda línea en el tratamiento de pacientes con carcinoma de células renales metastásico
ovartis Farmacéutica, S.A0 个研究点目标入组 427 人开始时间: 2009年8月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 427
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age ? 18 years old.
- •2. Patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell (or with a component of clear cell) or patients with non-clear cell renal carcinoma.
- •3. Patients with nephrectomy (partial or total) or without nephrectomy.
- •4. Patients with at least one measurable lesion at baseline as per the RECIST criteria. If skin lesions are reported as target lesions, they should be documented (at baseline and at every physical exam) using color photography and a measuring device (such as a caliper) in clear focus to allow the size of the lesion(s) to be determined from the photograph.
- •5. Patients with a Karnofsky Performance Status ?70%.
- •6. Adequate bone marrow function as shown by: ANC ? 1.5 x 109/L, Platelets ? 100 x 109/L, Hb >9 g/dL.
- •7. Adequate liver function: serum bilirubin: ? 1.5 x ULN, ALT and AST ? 2.5x ULN. Patients with known liver metastases: AST and ALT ? 5x ULN.
- •8. Adequate renal function: serum creatinine ? 2.0 x ULN.
- •9. Left ventricular ejection fraction (LVEF) ??lower limit of institutional normal (LLN) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. The same modality used at baseline should be applied for subsequent evaluations.
- •10. Women of childbearing potential must have had a negative serum pregnancy test within 14 days prior to the administration of the study medication.
- •11. Patients who give a written informed consent obtained according to local guidelines.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients within 4 weeks post-major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic), open biopsy, or significant traumatic injury to avoid wound healing complications. Minor procedures and percutaneous biopsies or placement of vascular access device require 7 days prior to study entry.
- •2. Patients who had radiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed within 2 weeks prior to study treatment start).
- •3. Patients in anticipation of the need for major surgical procedure during the course of the study.
- •4. Patients with a serious non-healing wound, ulcer, or bone fracture.
- •5. Patients with a history of seizure(s) not controlled with standard medical therapy.
- •6. Patients who have received prior systemic treatment for their metastatic RCC.
- •7. Patients who have previously received systemic mTOR inhibitors (sirolimus, temsirolimus, everolimus) or VEGF inhibitors.
- •8. Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients.
- •9. Patients with a known hypersensitivity to sunitinib or its excipients.
- •10. History or clinical evidence of central nervous system (CNS) metastases.
- •11. Clinically significant gastrointestinal abnormalities.
- •12. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ?160mmHg or diastolic blood pressure (DBP) of ? 95mmHg]. Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry.
- •13. Patients receiving chronic systemic treatment with corticosteroids (dose of ? 10 mg/day methylprednisone equivalent) or another immunosuppressive agent. Inhaled and topical steroids are acceptable.
- •14. Patients with a known history of HIV seropositivity.
- •15. Patients with active bleeding.
- •16. Patients who have any severe and/or uncontrolled medical conditions or other conditions within the past 12 months that could affect their participation in the study.
- •17. History of cerebrovascular accident (CVA) including transient ischemic attack (TIA) ? 6 months before start of study treatment.
- •18. History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.
- •19. Patients who have a history of another primary malignancy and off treatment for ? 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the uterine cervix or breast, and localized cancer of the bladder (T1) and prostate (T1 - T2).
- •20. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Oral contraceptives are not acceptable.
- •21. Patients who are using other investigational agents or who had received investigational drugs ? 2 weeks prior to study treatment start.
- •22. Patients unwilling or unable to comply with the protocol.
研究者
相似试验
进行中（未招募）
不适用
Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adultoEUCTR2005-001709-24-ESGrupo Español de Investigación en Sarcomas (GEIS)
进行中（未招募）
不适用
Estudio de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con irinotecán en pacientes con cáncer colorrectal metastásico con KRAS no mutado y refractario a la quimioterapia basada en irinotecán.Open, multicenter phase II study to evaluate the efficacy and safety of the combination of Panitumumab with Irinotecan in patients with Wild-Type KRAS metastatic colorectal cancer refractory to irinotecan based chemotherapy - SPECTRACáncer colorrectal metastástasico KRAS no mutado y refractarios a la quimioterápia basada en irinotecánEUCTR2009-010833-27-ESGrupo de Tratamiento de los Tumores Digestivos - TTD
进行中（未招募）
1 期
Estudio de fase 2, multicéntrico, en abierto, para evaluar la seguridad y la eficacia del IMC-1121B en combinación con 5-FU/AF y oxaliplatino (FOLFOX-6 modificado) como tratamiento de primera línea en pacientes con cáncer colorrectal metastásico.An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination with 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients with Metastatic Colorectal Cancer.Cáncer colorrectal metastásicoMetastatic Colorectal CancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2008-004936-19-ESImClone Systems Incorporated45
进行中（未招募）
1 期
Estudio en fase II, abierto, multicéntrico y aleatorizado de RO5083945 en combinación con FOLFIRI frente a FOLFIRI más cetuximab o FOLFIRI en monoterapia como tratamiento de segunda línea en pacientes con cáncer colorrectal metastásico con KRAS natural o mutado. A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type or mutant metastatic colorectal cancer .Cáncer colorrectal metastásico con o sin mutación de gen KRAS y con progresión de la enfermedad tras un tratamiento de primera línea mediante un régimen con oxaliplatino. Metastatic colorectal cancer, KRAS wild-type (WT) or mutant, with disease progression after first line treatment with an oxaliplatin-containing regimen.MedDRA version: 12.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2010-022983-11-ESF. Hoffmann-La Roche Ltd.169
进行中（未招募）
不适用
Estudio Multicéntrico, abierto y en fase II con Ipilimumab ( MDX-010) como extensión de tratamiento en monoterapia o seguimiento para pacientes previamente incluidos en Protocolos/Estudios con Ipilimumab ( MDX-010).Protocolo revisado 08, que incorpora las Cartas Administrativas 01 y 02 y las enmiendas 01,04,05,06,07,08,09, y 10 ( v.10.0 del 10 de septiembre de 2009)A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) ProtocolsRevised Protocol 08, incorporating Administrative Letter 01, 02, Amendments 01, 04, 05, 06, 07, 08, 09 and 10 (version 10.0, dated 10-Sep-09)EUCTR2005-006083-57-ESBristol-Myers Squibb International Corporation200